articleJournal of HepatologyJan 9, 2025Closed access

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials

JAJavier ArmisenMRMitra RauscheckerJSJaneli SarvMLMathias LiljebladLWLinda Wernevik

AstraZeneca (South Korea) · AstraZeneca (Poland) · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

47
total citations
FWCI
49.67
Percentile
100%
References
51
Citations per year

Authors

26

Topics & keywords

Topics
Keywords
  • Randomized controlled trial
  • Medicine
  • Internal medicine
  • Phase (matter)
  • Chemistry
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding